Regarding the previously described leukemia-supporting impact of IGF–IGF-1R signaling in leukemogenesis in AML [145], inhibition of IGF-1R using a neutralizing antibody and the IGF-1R kinase inhibitor NVP-AEW541 abrogated this pro-leukemic effect in vitro [144]. The gene discussed is IGF1R; the disease is acute myeloid leukemia.